A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

NCT04975308 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

874

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms
Neoplasm Metastasis

Interventions

DRUG: Imlunestrant
DRUG: Exemestane
DRUG: Fulvestrant
DRUG: Abemaciclib

Sponsor

Eli Lilly and Company